DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $30.60 billion. The enterprise value is $30.17 billion.
| Market Cap | 30.60B |
| Enterprise Value | 30.17B |
Important Dates
The last earnings date was Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 372.95 million shares outstanding. The number of shares has decreased by -3.92% in one year.
| Current Share Class | 372.95M |
| Shares Outstanding | 372.95M |
| Shares Change (YoY) | -3.92% |
| Shares Change (QoQ) | -1.69% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 102.40% |
| Float | 371.61M |
Valuation Ratios
The trailing PE ratio is 32.17 and the forward PE ratio is 27.82. DexCom's PEG ratio is 1.33.
| PE Ratio | 32.17 |
| Forward PE | 27.82 |
| PS Ratio | 5.99 |
| Forward PS | 5.45 |
| PB Ratio | 12.07 |
| P/TBV Ratio | 12.73 |
| P/FCF Ratio | 27.86 |
| P/OCF Ratio | 21.63 |
| PEG Ratio | 1.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.13, with an EV/FCF ratio of 27.47.
| EV / Earnings | 30.45 |
| EV / Sales | 5.91 |
| EV / EBITDA | 20.13 |
| EV / EBIT | 24.65 |
| EV / FCF | 27.47 |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.55.
| Current Ratio | 1.74 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | 0.91 |
| Debt / FCF | 1.27 |
| Interest Coverage | 91.33 |
Financial Efficiency
Return on equity (ROE) is 37.67% and return on invested capital (ROIC) is 45.93%.
| Return on Equity (ROE) | 37.67% |
| Return on Assets (ROA) | 11.13% |
| Return on Invested Capital (ROIC) | 45.93% |
| Return on Capital Employed (ROCE) | 30.70% |
| Weighted Average Cost of Capital (WACC) | 11.69% |
| Revenue Per Employee | $459,856 |
| Profits Per Employee | $89,279 |
| Employee Count | 11,100 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.72 |
Taxes
In the past 12 months, DexCom has paid $271.40 million in taxes.
| Income Tax | 271.40M |
| Effective Tax Rate | 21.50% |
Stock Price Statistics
The stock price has increased by +41.30% in the last 52 weeks. The beta is 1.44, so DexCom's price volatility has been higher than the market average.
| Beta (5Y) | 1.44 |
| 52-Week Price Change | +41.30% |
| 50-Day Moving Average | 84.12 |
| 200-Day Moving Average | 75.17 |
| Relative Strength Index (RSI) | 48.84 |
| Average Volume (20 Days) | 5,196,842 |
Short Selling Information
The latest short interest is 15.93 million, so 4.27% of the outstanding shares have been sold short.
| Short Interest | 15.93M |
| Short Previous Month | 15.69M |
| Short % of Shares Out | 4.27% |
| Short % of Float | 4.29% |
| Short Ratio (days to cover) | 3.52 |
Income Statement
In the last 12 months, DexCom had revenue of $5.10 billion and earned $991.00 million in profits. Earnings per share was $2.55.
| Revenue | 5.10B |
| Gross Profit | 3.24B |
| Operating Income | 1.22B |
| Pretax Income | 1.26B |
| Net Income | 991.00M |
| EBITDA | 1.50B |
| EBIT | 1.22B |
| Earnings Per Share (EPS) | $2.55 |
Balance Sheet
The company has $1.82 billion in cash and $1.39 billion in debt, with a net cash position of $425.00 million or $1.14 per share.
| Cash & Cash Equivalents | 1.82B |
| Total Debt | 1.39B |
| Net Cash | 425.00M |
| Net Cash Per Share | $1.14 |
| Equity (Book Value) | 2.54B |
| Book Value Per Share | 6.80 |
| Working Capital | 1.66B |
Cash Flow
In the last 12 months, operating cash flow was $1.41 billion and capital expenditures -$316.10 million, giving a free cash flow of $1.10 billion.
| Operating Cash Flow | 1.41B |
| Capital Expenditures | -316.10M |
| Depreciation & Amortization | 275.00M |
| Net Borrowing | -1.21B |
| Free Cash Flow | 1.10B |
| FCF Per Share | $2.94 |
Margins
Gross margin is 63.42%, with operating and profit margins of 23.98% and 19.41%.
| Gross Margin | 63.42% |
| Operating Margin | 23.98% |
| Pretax Margin | 24.73% |
| Profit Margin | 19.41% |
| EBITDA Margin | 29.36% |
| EBIT Margin | 23.98% |
| FCF Margin | 21.52% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 3.92% |
| Shareholder Yield | 3.92% |
| Earnings Yield | 3.11% |
| FCF Yield | 3.59% |
Analyst Forecast
The average price target for DexCom is $98.58, which is 20.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $98.58 |
| Price Target Difference | 20.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (3Y) | 11.21% |
| EPS Growth Forecast (3Y) | 20.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 6.93 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.93 |
| Piotroski F-Score | 7 |